{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-167089","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.227425+00:00","generated_at":"2026-05-17T23:47:34.433906+00:00","sec_items":["2.01","1.01","3.02","9.01","5.02","3.03","5.01","5.03","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis","bullets":["Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.","Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.","Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.","CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.","PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-167089","json":"https://secwatch.observer/filing/0001193125-25-167089.json","markdown":"https://secwatch.observer/filing/0001193125-25-167089.md","text":"https://secwatch.observer/filing/0001193125-25-167089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:47:34.433906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c418773369a6c38326fb1c78bb33e28e0a10263","claim":"ImageneBio, Inc.: Company ceased to be a shell company as a result of the Merger.","evidence_excerpt":"As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"bdc45e6bef334f926408d63ff00ec23f4df7ef13","claim":"ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals for Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock (closed 2025-07-25).","evidence_excerpt":"Time were canceled and ceased to exist, and no consideration was delivered in exchange therefor, (b) each then-outstanding Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock, par value $0.001 per share (“ Ikena Common Stock ”) (such ratio, the “ Exchange Ratio ”) and (c) each then-outstanding option to purchase Inmagene","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Inmagene Biopharmaceuticals"},{"label":"Consideration","value":"Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock"},{"label":"Closing","value":"2025-07-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}